Undertaking Phase 1 clinical trials in Australia during a time of uncertainty
10 steps to successfully navigating your next clinical trial
In the presence of challenges facing our industry as a result of Coronavirus (COVID-19), Nucleus Network has developed this comprehensive ten-step white paper to help you navigate successful Phase 1 clinical trials in Australia.
Our preparedness as a business to continue to operate and support the clinical trial requirements of our biotech, pharmaceutical and CRO clients is guided by 10 key pillars:
- Multi-Site reach in Australia
- Size, scale and savings
- World-class medical precincts
- Social distancing measures
- Robust participant pipeline
- Rigorous participant screening
- Dedicated trial teams
- Gold standard infection control
- Cross-functional response team
- Supply chain surety
These 10 key pillars underpin our processes, behaviours and values as Australia’s largest Phase 1 clinical trials provider. They also ensure we can continue to support our clients’ clinical trials requirements during this pandemic crisis and prepare them well for the next large-scale challenge.
Nucleus is the vital first step in unlocking the next generation of vaccines.
Please enter your contact details below to download the white paper.